Ovarian hyperstimulation syndrome: symptoms, risks and prevention
Ovarian hyperstimulation syndrome (OHSS) is an uncommon but potentially serious complication of fertility treatment. It occurs when over-responsive ovaries become enlarged and fluid moves from the bloodstream into the abdominal cavity. The result can be painful swelling, dehydration and, in severe cases, breathing difficulty or blood clots. Early recognition matters, especially after an egg collection trigger, embryo transfer or during early pregnancy.
Most recognised cases are mild and resolve with monitoring, but symptoms can develop quickly. Understanding the risk factors, warning signs and preventive strategies helps patients make informed decisions and seek care without unnecessary delay. This guide explains how OHSS develops, who may be more vulnerable and what to discuss with a fertility specialist before treatment begins.
What ovarian hyperstimulation syndrome is
During IVF, fertility medicines stimulate several ovarian follicles to develop. In some patients, the ovaries produce an unusually strong response, leading to enlarged ovaries and increased vascular permeability. Fluid can then escape from small blood vessels and collect in the abdomen, a condition called ascites. Reduced circulating blood volume may also affect kidney function and increase the risk of thrombosis.
OHSS most often appears within one to ten days of the trigger injection used to mature eggs or following egg collection. A pregnancy-related form can develop after embryo transfer because the developing placenta produces human chorionic gonadotropin, or hCG. Mild symptoms may include bloating and pelvic discomfort, while severe OHSS can involve substantial fluid retention, pleural effusion, kidney injury or blood clots in the legs, lungs or other veins.
The risk cannot be predicted perfectly. Some high-risk patients have no symptoms, while others develop noticeable problems despite a carefully adjusted protocol. This is why ultrasound findings, hormone results, fluid balance and patient feedback are assessed together rather than relying on one measurement alone.
Symptoms and warning signs
Symptoms that may indicate mild or moderate OHSS should be reported promptly to the treating clinic, even if they seem manageable. Common signs include:
- Increasing abdominal bloating or a feeling of tightness and fullness
- Pelvic discomfort, cramping or tenderness
- Nausea, vomiting, diarrhoea or loss of appetite
- Rapid weight gain, mild swelling or a noticeable reduction in urine output
Some early symptoms overlap with ordinary post-treatment discomfort, which can make them easy to dismiss. A patient who feels more swollen than usual after ovarian stimulation should contact the clinic rather than wait for the next routine appointment. Tracking symptoms alongside blood tests and ultrasound scans gives the medical team a clearer picture of ovarian response and fluid status.
Emergency warning signs require immediate medical attention rather than a routine call to the fertility team:
- Severe or worsening abdominal pain, a rigid abdomen or marked abdominal swelling
- Shortness of breath, chest pain, coughing blood or a very fast heartbeat
- Fainting, confusion, extreme weakness, severe dizziness or inability to keep fluids down
- Very little or no urine, significant blood in the urine or heavy vaginal bleeding
Patients should tell emergency clinicians about their recent IVF treatment, trigger injection, egg collection or embryo transfer. This information can help them identify OHSS and exclude other urgent complications. In Australia, call 000 for an ambulance; anyone receiving treatment overseas should use the local emergency number. Do not drive yourself if you have chest pain, breathing difficulty, faintness or severe abdominal pain.
Factors that increase the risk
Polycystic ovary syndrome is one of the strongest clinical risk factors. High levels of anti-Müllerian hormone, a large antral follicle count and a previous response to ovarian stimulation can also suggest that the ovaries may be highly sensitive. Other associated factors include low body mass index, a previous episode of OHSS, being a young egg donor and producing a large number of eggs during the current cycle.
Treatment-related factors include a high dose of gonadotropin medication, prolonged ovarian stimulation and the use of an hCG trigger. The actual response to the medication remains important because some patients have several risk factors without developing OHSS, while others experience it despite a reassuring assessment. Age alone does not determine the outcome.
Risk assessment should therefore include previous IVF cycles, hormone results, ultrasound findings, medical history and the medications selected for the current treatment. Stress and anxiety can affect how treatment feels and whether symptoms are noticed promptly, but they do not cause OHSS. An experienced specialist can identify risk while avoiding unnecessary reductions in treatment that might affect the chance of success.
How clinics reduce the risk
Care begins before the first injection. A fertility specialist reviews ovarian reserve indicators such as anti-Müllerian hormone and antral follicle count, along with previous egg yields and any history of OHSS. A practical fertility calendar guide can help organise menstrual dates, test results and details of earlier treatment cycles. Tracking provides useful context, although it cannot guarantee that a low-risk cycle will remain uncomplicated.
The medication dose and protocol are then tailored to the expected response. An antagonist protocol may be used because it gives the clinician flexibility to adjust stimulation and choose a trigger that carries less OHSS risk in appropriate cases. A GnRH agonist trigger can be an alternative to hCG, particularly when all suitable embryos will be frozen. Cancellation before egg collection is another option if the response becomes excessive.
Reduced-dose stimulation, sometimes offered as Mini IVF, may suit selected patients. The name alone does not make the cycle risk-free, so dosing decisions should depend on ovarian reserve, medical history and the individual response. Monitoring with transvaginal ultrasound and estradiol measurements, together with symptom review, helps the team assess follicular growth and decide when to trigger, continue or stop stimulation.
After egg collection, follow-up may include weight checks, urine output, vital signs, blood tests and ultrasound. Fluid and medication advice should be based on the clinic’s protocol and the patient’s risk level. A freeze-all plan can reduce the risk from hCG produced during the luteal phase or early pregnancy, but it does not prevent every case of early post-retrieval OHSS. Clear communication about what to monitor and whom to call is an essential part of prevention.
Treatment planning in Australia and overseas
Australian fertility care has several practical realities. Melbourne and Sydney are major IVF hubs, and many patients travel from regional areas or interstate for scans, blood tests and appointments. IVF is generally paid privately here because Medicare does not routinely rebate it, while many private health policies exclude assisted reproduction. An itemised treatment estimate can therefore help with budgeting, including consultations, tests, medicines, procedures and any additional monitoring.
Australians often describe IVF as a full-on emotional rollercoaster, and the treatment demands can feel especially intense for people managing work, travel and family commitments. Donor treatment and surrogacy also involve state-based legal requirements, screening and documentation. Patients considering these pathways should obtain advice from a qualified fertility lawyer and their treating clinic before treatment begins.
For Australians considering care in Mumbai, travel planning and aftercare deserve close attention. A long-haul journey can make timely monitoring more difficult if a complication appears after egg collection. Resources such as overseas patient planning can help patients compare clinical credentials, communication arrangements, travel requirements and post-treatment support. The treating team should remain accessible throughout the recovery period, and patients should know which local medical facility can provide urgent care.
Indo Nippon IVF is a Mumbai-based fertility and reproductive medicine clinic offering IVF, Mini IVF, ICSI, IUI, donor egg IVF, egg freezing, embryo transfer, surrogacy and pre-implantation genetic testing. Its specialist team, advanced laboratory technologies and experience with patients from India and overseas support customised, appointment-based care for individuals and couples.
If you are preparing for IVF, request an individualised OHSS risk assessment, agree on monitoring and aftercare before medication begins, and keep the clinic’s emergency contact details readily available. For treatment in Mumbai, contact Indo Nippon IVF to arrange a consultation that accounts for your medical history, previous cycles and travel plans.